JNJ Talc Powder Claims Surge to 7,111
Key Questions
How many talc powder claims are now against Johnson & Johnson?
Claims have surged to 7,111, with UK claimants alleging asbestos-related cancer. This creates a legal overhang amid ongoing disputes.
What is the current stock price reaction to JNJ talc lawsuits?
The stock dipped to around $227 due to the news. However, legal clouds are lifting, viewed as noise against solid fundamentals.
What do analysts say about JNJ stock amid talc claims?
Analysts rate it Moderate Buy with a $252 price target, implying over 10% upside. Solid dividends provide support versus the litigation noise.
Is Johnson & Johnson considered a 'forever stock'?
Yes, it's listed among forever stocks like ExxonMobil and Walmart for long-term watchlists. Its accelerating growth justifies a higher multiple despite challenges.
Are there concerns about JNJ being overvalued?
Discussions note overvalued stocks from high expectations and past growth. However, JNJ's growth thesis counters this, with some funds like Oppenheimer lessening holdings.
UK claimants up alleging asbestos-cancer; overhang amid disputes but stock ~$227 dip, analysts Moderate Buy PT $260 (15% upside), solid divs outweigh noise.